Avalo Therapeutics (NASDAQ:AVTX) Issues Quarterly Earnings Results

Avalo Therapeutics (NASDAQ:AVTX) released its quarterly earnings results on Wednesday. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02, FiscalAI reports.

Avalo Therapeutics Stock Performance

AVTX stock traded down $0.09 during trading on Wednesday, reaching $19.85. 1,556,069 shares of the company were exchanged, compared to its average volume of 1,011,846. The company has a market cap of $530.27 million, a P/E ratio of -3.46 and a beta of 0.78. Avalo Therapeutics has a 52-week low of $3.39 and a 52-week high of $24.27. The stock’s 50 day moving average price is $15.80 and its 200 day moving average price is $16.43.

Insider Buying and Selling

In related news, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the sale, the insider owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.01, for a total transaction of $71,499.70. Following the sale, the insider directly owned 3,622 shares in the company, valued at approximately $65,232.22. This represents a 52.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 138,078 shares of company stock valued at $2,501,346. Corporate insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new stake in Avalo Therapeutics during the fourth quarter worth $742,000. XTX Topco Ltd boosted its position in Avalo Therapeutics by 190.0% during the fourth quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock worth $735,000 after purchasing an additional 26,508 shares in the last quarter. Two Sigma Investments LP boosted its position in Avalo Therapeutics by 282.0% during the third quarter. Two Sigma Investments LP now owns 49,242 shares of the company’s stock worth $626,000 after purchasing an additional 36,353 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in Avalo Therapeutics during the fourth quarter worth $586,000. Finally, Geode Capital Management LLC boosted its position in Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares in the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AVTX has been the topic of several research analyst reports. BTIG Research lifted their price target on Avalo Therapeutics from $40.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. HC Wainwright lifted their price target on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Citizens Jmp boosted their target price on Avalo Therapeutics from $52.00 to $62.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Piper Sandler reissued an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday. Finally, Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Avalo Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $49.63.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.